1-5 of 5
Marshall S. Flam, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD
Journal: Blood
Blood (2015) 126 (23): 5383.
https://doi.org/10.1182/blood.V126.23.5383.5383
Published: 2015
Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2014) 124 (21): 4774.
https://doi.org/10.1182/blood.V124.21.4774.4774
Published: 2014
Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

James R. Berenson, MD, Ori Yellin, MD, Alan D. Cartmell, MD, Thomas B. S. Woliver, MD, Marshall S. Flam, MD, Youram Nassir, MD, Robert Vescio, MD, Regina A. Swift, RN
Journal: Blood
Blood (2010) 116 (21): 3044.
https://doi.org/10.1182/blood.V116.21.3044.3044
Published: 2010
Journal Articles

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

James R. Berenson, MD, Ori Yellin, MD, Donald Woytowitz, MD, Marshall S. Flam, MD, Alan Cartmell, MD, Ravi Patel, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN
Journal: Blood
Blood (2007) 110 (11): 3602.
https://doi.org/10.1182/blood.V110.11.3602.3602
Published: 2007
Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN
Journal: Blood
Blood (2007) 110 (11): 3606.
https://doi.org/10.1182/blood.V110.11.3606.3606
Published: 2007